Advertisement

Supply Chain



The Food and Drug Administration on Tuesday approved a new use for Merck's best-selling cancer drug, Keytruda, based on a patient's individual genetic makeup, rather than the physical location of the tumor, reports Reuters.

Some of the most expensive medications on the market treat a rare disease or cancer, and often represent the first approved treatment for the condition, according to a study from Waltham, Mass.–based life science consulting firm Trinity Partners.

Advertisement

Most Read

Advertisement
Advertisement